Find a Clinical Trial

Filter

Showing 1 - 2 out of 2

DEFENDO Long-Term Follow-Up Study

A long-term extension study to evaluate the safety and efficacy of OXERVATE 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 Neurotrophic Keratitis who enrolled in the DEFENDO Study

Neurotrophic keratitis

All genders

18+

Recruiting now

Department of Ophthalmology

Tufts Medical Center

Learn more

SEER-2

A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)

Neurotrophic keratitis

All genders

18+

Recruiting now

Department of Ophthalmology

Tufts Medical Center

Learn more

Language 1

Language 2

Language 3

Privacy on this site

We collect and process your data on this site to better understand how it is used. You can give your consent to all or selected purposes, or you can decline them all. For more information, see our privacy policy.

Analytics

Marketing automation

AnalyticsWe'll collect information about your visit to our site. It helps us understand how the site is used – what's working, what might be broken and what we should improve.

Marketing automationWe'll use your data to send you more relevant email or text message campaigns. We'll also use it to exclude you from campaigns that you might not like.

Powered by

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A long-term extension study to evaluate the safety and efficacy of OXERVATE 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 Neurotrophic Keratitis who enrolled in the DEFENDO Study

A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)